Merck Sharp & Dohme (New Zealand) Limited (MSD) is a subsidiary of Merck & Co. Inc. MSD was established in New Zealand in 1962.
In New Zealand, MSD provides medicines, vaccines and biologic therapies across a broad range of therapeutic areas. These include; oncology, anaesthesia, HIV/AIDS, antibacterials/antifungals and immunisations.
MSD is one of the few pharmaceutical companies still conducting clinical trials in New Zealand and invests approximately $NZ78 million in local clinical research.1 Current research programmes include oncology, infectious diseases, endocrinology, chronic cough and vaccines.
For enquiries contact Claire Graham